Get the Stockscreener App
6.18
2.37%
-0.15
After Hours:
5.50
-0.68
-11.00%
Biodexa Pharmaceuticals Plc Adr stock is traded at $6.18, with a volume of 2.39M.
It is down -2.37% in the last 24 hours and down -7.76% over the past month.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$6.33
Open:
$5.86
24h Volume:
2.39M
Relative Volume:
13.75
Market Cap:
$3.83M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.00738
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
-17.01%
1M Performance:
-7.76%
6M Performance:
-55.86%
1Y Performance:
-89.54%
1-Day Range:
$5.00
$6.22
1-Week Range:
$5.00
$7.6204
52-Week Range:
$5.00
$92.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
6.18 | 3.92M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Biodexa receives EMA approval for phase 3 FAP treatment trial - Investing.com
Biodexa (NASDAQ: BDRX) sets first EU enrollment for 4Q 2025 after EMA CTA approval - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy? - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Given Sell (E+) Rating at Weiss Ratings - Defense World
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Canada
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News - GuruFocus
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change By Investing.com - Investing.com Canada
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan
Biodexa Announces Activation of First Clinical Study Site - GlobeNewswire
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):